Related Experiment Video

Updated: May 20, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

MDM4 is a key therapeutic target in cutaneous melanoma

Agnieszka Gembarska1, Flavie Luciani, Clare Fedele

  • 1Center for the Biology of Disease, Laboratory for Molecular Cancer Biology, Vlaams Instituut voor Biotechnologie (VIB), Leuven, Belgium; Center for Human Genetics, Katholieke Universiteit (KU) Leuven, Leuven, Belgium.

Nature Medicine
|July 24, 2012
PubMed

Insights

Melanoma bypasses p53 tumor suppression via MDM4 upregulation. Inhibiting MDM4 restores p53 function, increasing melanoma sensitivity to chemotherapy and BRAF inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • p53 pathway inactivation is crucial in many cancers, often via TP53 mutations.
  • Melanoma, a chemotherapy-resistant cancer, rarely harbors TP53 mutations, suggesting alternative tumor suppression evasion mechanisms.
  • MDM4 (Mdm4 p53 binding protein homolog) is a negative regulator of p53.

Purpose of the Study:

  • To investigate the role of MDM4 in melanoma tumorigenesis and p53 pathway regulation.
  • To determine if MDM4 is a viable therapeutic target in melanoma.

Main Methods:

  • Analysis of MDM4 expression in human melanoma tissues (stage I-IV).
  • Generation of a mouse model with melanocyte-specific Mdm4 overexpression and Nras-induced melanoma.
  • Assessment of MDM4-p53 interaction inhibition on p53 function, apoptosis, and sensitivity to chemotherapy and BRAF (V600E) inhibitors in melanoma cells.

Main Results:

  • MDM4 is upregulated in approximately 65% of human melanomas.
  • Overexpression of Mdm4 in mice promoted melanoma development.
  • MDM4 antagonizes p53's proapoptotic function, promoting survival in metastatic melanoma.
  • Inhibiting the MDM4-p53 interaction reactivated p53, enhancing sensitivity to chemotherapy and BRAF inhibitors.

Conclusions:

  • MDM4 is a key factor in the impaired p53 function observed in human melanoma.
  • MDM4 represents a promising therapeutic target for combination therapies against melanoma.

More Related Videos

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...